
    
      A 24-month randomized, single-blind, placebo-controlled trial to investigate the efficacy of
      empagliflozin to reduce atrial fibrillation burden in patients with diabetes mellitus or
      overweight, heart failure and atrial fibrillation in which a rhythm control strategy is
      indicated.
    
  